Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Pneumonia

The investigations of Jensen and Schmith (45) indicate that in vitro activity of 2-sulfanilamido and 4-methyl-2-sulfanilamido selenazoles against pneumonia infections is comparable to that of sulfathiazole or sulfadiazine. Frisk (47) found that the activity of the selenium compounds was much lower than that of sulfathiazole. [Pg.249]

We tend to take the efficacy of modern drugs for granted One comparison with the not too distant past might put this view into better perspec tive Once sulfa drugs were introduced in the United States the number of pneumonia deaths alone de creased by an estimated 25 000 per year The sulfa... [Pg.952]

The bacterium was Strepto coccus pneumoniae also called Pneumococcus... [Pg.1166]

Paraffins. Methane and ethane are simple asphyxiants, whereas the higher homologues are central nervous system depressants. Liquid paraffins can remove oil from exposed skin and cause dermatitis or pneumonia in lung tissue. Generally, paraffins are the least toxic class of hydrocarbons. [Pg.370]

Pneumogstis carini pneumonia (PCP), the most common of the opportunistic infections, occurs in more than 80% of AIDS patients (13). Toxoplasmosis, a proto2oan infection of the central nervous system, is activated in AIDS patients when the 004 count drops and severe impairment of ceU-mediated immunity occurs. Typically, patients have a mass lesion(s) in the brain. These mass lesions usually respond well to therapy and can disappear completely. Fungal infections, such as CTyptococcalmeningitis, are extremely common in AIDS patients, and Histop/asma capsulatum appears when ceU-mediated immunity has been destroyed by the HIV vims, leading to widespread infection of the lungs, Hver, spleen, lymph nodes, and bone marrow. AIDS patients are particularly susceptible to bacteremia caused by nontyphoidal strains of Salmonella. Bacteremia may be cleared by using antibiotic therapy. [Pg.33]

Magnesium vanadates, as vanadium compounds in general, are known irritants of the respiratory tract and conjunctiva. The threshold limit value (TLV) for vanadium compounds in air recommended by the National Institute of Occupational Safety and Health is 0.05 mg/m based on a typical 8-h workday and 40-h workweek (7,147). Chronic inhalation can lead to lung diseases such as bronchitis, bronchopneumonia, and lobar pneumonia. These dust-related effects can be avoided by use of individual respirators in areas where exposure is likely. [Pg.360]

In Vivo Properties. The efficacy of dalbaheptides has been assessed ia various models of experimental septicemia ia mice. In general there was good correlation between the ED qS (effective doses which prevent death ia 50% of test animals) and the MICs on test strains. Teicoplanin was very effective, ED q values ranged from 0.11 to 0.72 mg/kg sc administration for septicemias caused by S. pyogenes S. pneumoniae and S. aureu whereas for vancomycin ED qS were from 0.58 to 7.2 mg/kg (33). Eremomycin (52) had therapeutic activity 2—3 times greater than vancomycin. Therapeutic indices... [Pg.537]

In 1956 selenium was identified (123) as an essential micronutrient iu nutrition. In conjunction with vitamin E, selenium is effective iu the prevention of muscular dystrophy iu animals. Sodium selenite is adrninistered to prevent exudative diathesis iu chicks, a condition iu which fluid leaks out of the tissues white muscle disease iu sheep and infertility iu ewes (see Eeed ADDITIVES). Selenium lessens the iacidence of pneumonia iu lambs and of premature, weak, and stillborn calves controls hepatosis dietetica iu pigs and decreases muscular inflammation iu horses. White muscle disease, widespread iu sheep and cattle of the selenium-deficient areas of New Zealand and the United States, is insignificant iu high selenium soil areas. The supplementation of animal feeds with selenium was approved by the U.S. EDA iu 1974 (see Eeed additives). Much of selenium s metaboHc activity results from its involvement iu the selenoproteia enzyme, glutathione peroxidase. [Pg.337]

Vaccines can be roughly categorized into killed vaccines and Hve vaccines. A killed vaccine can be (/) an inactivated, whole microorganism such as pertussis, (2) an inactivated toxin, called toxoid, such as diphtheria toxoid, or (J) one or more components of the microorganism commonly referred to as subunit vaccines. The examples are capsular polysaccharide of Streptococcus pneumoniae and the surface antigen protein for Hepatitis B vims vaccine. [Pg.356]

Vaccines for special populations are Hsted in Table 2. Two vaccines that are in fairly widespread use in the adult population are vaccines that prevent viral influenza and pneumococcal pneumonia. [Pg.358]

Parainfluenza. Parainfluenza vimses (PIV) also causes viral pneumonia in infants. It is similar to RSV, therefore similar approaches are being used for developing a vaccine. A five attenuated PIV-3 vaccine has been in clinical trial (74). [Pg.359]

Cost—benefit analyses for adult immunizations have also been performed. Influenza immunization during the period from 1971 to 1977 resulted in over 13 million more years of life at a cost of only 63 per year of life gained. Productivity gains were estimated to have a value of 250 x 10 (148). Projected costs of pneumonia have been calculated at 3.6 times the cost of vaccination, or a savings of 141 per person is achieved among those at risk for developing pneumonia or over the age of 50 years (149). [Pg.362]

Cefuroxime (35) is effective against community-acquired pneumonia in which ampicillin-resistant Haemophilus influence is the probable etiologic agent. Cefoxitin (23) is used to treat mixed aerobic—anaerobic infections including pelvic infections, intra-abdorninal infections, and nosocomial aspiration pneumonia. Cefonicid (31), because of its long half-life has been used in a once-a-day regimen to treat a variety of mild to moderate infections including community-acquired pneumonias, urinary tract infections, and infections of the skin and soft tissue (132,215). [Pg.39]

M ribosomal protection Neisseria, Mycoplasma, Ureaplasma, Haemophilus, Campylobacter, Clostridium, Enterococcus, Staphylococcus, Streptococcus Gardnerella, Kingella, Eikenella, Veillonella, Tusobacterium, Peptostreptococcus Clostridium difficile. Streptococcus pneumoniae... [Pg.182]


See other pages where Pneumonia is mentioned: [Pg.193]    [Pg.545]    [Pg.545]    [Pg.593]    [Pg.650]    [Pg.773]    [Pg.773]    [Pg.921]    [Pg.933]    [Pg.147]    [Pg.253]    [Pg.498]    [Pg.303]    [Pg.47]    [Pg.87]    [Pg.87]    [Pg.482]    [Pg.511]    [Pg.514]    [Pg.514]    [Pg.342]    [Pg.359]    [Pg.303]    [Pg.23]    [Pg.27]    [Pg.28]    [Pg.28]    [Pg.39]    [Pg.39]    [Pg.39]    [Pg.45]    [Pg.62]    [Pg.83]    [Pg.108]    [Pg.108]    [Pg.156]    [Pg.269]   
See also in sourсe #XX -- [ Pg.1049 , Pg.1050 , Pg.1051 , Pg.1052 , Pg.1053 , Pg.1054 , Pg.1055 , Pg.1056 , Pg.1057 , Pg.1058 ]

See also in sourсe #XX -- [ Pg.2 , Pg.50 , Pg.161 ]

See also in sourсe #XX -- [ Pg.259 ]

See also in sourсe #XX -- [ Pg.56 , Pg.61 , Pg.71 ]

See also in sourсe #XX -- [ Pg.471 , Pg.472 , Pg.473 , Pg.474 , Pg.475 , Pg.476 ]

See also in sourсe #XX -- [ Pg.21 ]

See also in sourсe #XX -- [ Pg.266 , Pg.278 , Pg.279 , Pg.282 ]

See also in sourсe #XX -- [ Pg.64 , Pg.73 ]

See also in sourсe #XX -- [ Pg.77 , Pg.88 ]

See also in sourсe #XX -- [ Pg.56 , Pg.61 , Pg.71 ]

See also in sourсe #XX -- [ Pg.591 ]

See also in sourсe #XX -- [ Pg.254 ]

See also in sourсe #XX -- [ Pg.73 , Pg.85 , Pg.109 , Pg.202 , Pg.235 , Pg.348 ]

See also in sourсe #XX -- [ Pg.515 , Pg.516 , Pg.517 ]

See also in sourсe #XX -- [ Pg.405 , Pg.406 , Pg.407 , Pg.408 , Pg.409 ]

See also in sourсe #XX -- [ Pg.48 ]

See also in sourсe #XX -- [ Pg.155 , Pg.163 ]

See also in sourсe #XX -- [ Pg.344 ]

See also in sourсe #XX -- [ Pg.19 ]

See also in sourсe #XX -- [ Pg.64 ]

See also in sourсe #XX -- [ Pg.16 ]

See also in sourсe #XX -- [ Pg.471 , Pg.472 , Pg.473 , Pg.474 , Pg.475 , Pg.476 ]

See also in sourсe #XX -- [ Pg.132 ]

See also in sourсe #XX -- [ Pg.2473 ]

See also in sourсe #XX -- [ Pg.119 ]

See also in sourсe #XX -- [ Pg.40 , Pg.239 , Pg.240 ]

See also in sourсe #XX -- [ Pg.23 ]

See also in sourсe #XX -- [ Pg.169 ]

See also in sourсe #XX -- [ Pg.56 , Pg.61 , Pg.71 ]

See also in sourсe #XX -- [ Pg.156 , Pg.326 ]

See also in sourсe #XX -- [ Pg.1944 , Pg.1951 , Pg.1952 , Pg.1953 , Pg.1954 , Pg.1955 , Pg.1956 , Pg.1957 , Pg.1958 , Pg.1959 ]

See also in sourсe #XX -- [ Pg.67 , Pg.77 ]

See also in sourсe #XX -- [ Pg.577 ]

See also in sourсe #XX -- [ Pg.2 , Pg.114 , Pg.115 ]

See also in sourсe #XX -- [ Pg.4 , Pg.5 , Pg.6 , Pg.7 , Pg.8 , Pg.9 , Pg.10 , Pg.11 , Pg.12 , Pg.13 , Pg.14 , Pg.15 , Pg.16 , Pg.17 , Pg.18 , Pg.19 , Pg.20 , Pg.21 , Pg.22 , Pg.23 , Pg.51 , Pg.55 ]

See also in sourсe #XX -- [ Pg.6 ]

See also in sourсe #XX -- [ Pg.87 ]

See also in sourсe #XX -- [ Pg.195 ]

See also in sourсe #XX -- [ Pg.64 , Pg.74 ]

See also in sourсe #XX -- [ Pg.777 ]

See also in sourсe #XX -- [ Pg.772 , Pg.787 , Pg.788 , Pg.797 , Pg.800 , Pg.803 ]

See also in sourсe #XX -- [ Pg.280 ]

See also in sourсe #XX -- [ Pg.261 ]

See also in sourсe #XX -- [ Pg.14 , Pg.78 , Pg.88 , Pg.404 , Pg.408 ]

See also in sourсe #XX -- [ Pg.35 , Pg.126 , Pg.142 ]

See also in sourсe #XX -- [ Pg.506 , Pg.623 ]

See also in sourсe #XX -- [ Pg.26 , Pg.183 , Pg.208 , Pg.255 , Pg.264 ]

See also in sourсe #XX -- [ Pg.534 ]

See also in sourсe #XX -- [ Pg.10 ]

See also in sourсe #XX -- [ Pg.92 ]

See also in sourсe #XX -- [ Pg.458 ]

See also in sourсe #XX -- [ Pg.190 ]

See also in sourсe #XX -- [ Pg.34 , Pg.102 , Pg.119 , Pg.120 , Pg.129 , Pg.149 , Pg.180 , Pg.195 , Pg.218 , Pg.242 , Pg.245 , Pg.250 , Pg.258 ]

See also in sourсe #XX -- [ Pg.23 , Pg.80 ]

See also in sourсe #XX -- [ Pg.51 , Pg.261 ]

See also in sourсe #XX -- [ Pg.489 ]

See also in sourсe #XX -- [ Pg.816 ]

See also in sourсe #XX -- [ Pg.357 ]

See also in sourсe #XX -- [ Pg.264 ]

See also in sourсe #XX -- [ Pg.122 , Pg.128 ]

See also in sourсe #XX -- [ Pg.188 ]

See also in sourсe #XX -- [ Pg.105 ]

See also in sourсe #XX -- [ Pg.706 ]

See also in sourсe #XX -- [ Pg.629 , Pg.634 , Pg.654 , Pg.656 , Pg.657 , Pg.662 ]




SEARCH



Acute Interstitial Pneumonia (AIP)

Acute fibrinous and organizing pneumonia

Acute interstitial pneumonia

Acute interstitial pneumonia pathology

American Thoracic Society pneumonia

Amoxicillin in pneumonia

Amoxicillin-clavulanate in pneumonia

Ampicillin in pneumonia

Ampicillin-sulbactam in pneumonia

Antibiotics community-acquired pneumonia

Aspiration postoperative pneumonia

Aspirin pneumonia

Associated Pneumonia

Atypical pneumonia

Azithromycin in pneumonia

Bacteria Klebsiella pneumoniae

Bacterial infections pneumonia

Bacterial nosocomial pneumonia

Bacterial nosocomial pneumonia pathogens

Bacterial nosocomial pneumonia treatment

Bacterial pneumonia tetracyclines

Biliary pneumonia

Bone marrow transplantation idiopathic pneumonia syndrome

Bronchiolitis obliterans organising pneumonia

Bronchiolitis obliterans organizing pneumonia

Bronchiolitis obliterans organizing pneumonia BOOP)

Bronchitis pneumonia

C. pneumoniae

Calculating Nosocomial Pneumonia Rates

Capsular polysaccharide from Streptococcus pneumoniae

Ceftazidime in pneumonia

Ceftriaxone in pneumonia

Children Pneumocystis carinii pneumonia

Children nosocomial pneumonia

Children pneumonia

Chlamydia infections pneumonia

Chlamydia pneumoniae

Chlamydia pneumoniae infections

Chlamydia pneumoniae, and

Chlamydophila pneumoniae

Chronic eosinophilic pneumonia

Chronic obstructive pulmonary disease pneumonia

Ciprofloxacin in pneumonia

Clarithromycin in pneumonia

Cocaine pneumonia

Cryptococcal pneumonia

Cryptogenic organizing pneumonia

Cytomegalovirus infection pneumonia

Desquamative interstitial pneumonia

Desquamative interstitial pneumonia histopathology

Desquamative interstitial pneumonia pathology

Diagnosis of Pneumonia Using Bronchoscopic Techniques

Diagnosis of Pneumonia Using Nonbronchoscopic Techniques

Diplococcus pneumonia, polysaccharides

Diplococcus pneumoniae

Diplococcus pneumoniae, transformation

Diplococcus pneumoniae, treatment

Drugs for toxoplasma and pneumocystis pneumonia

Early Nosocomial Pneumonia

Elderly pneumonia

Endotracheal aspirates nosocomial pneumonia

Eosinophihc pneumonia

Eosinophilic Pneumonia of Undetermined Origin

Eosinophilic pneumonia

Erythromycin in pneumonia

Essential oils pneumoniae

Fungal pneumonias

Gatifloxacin in pneumonia

Gentamicin in pneumonia

Glucocorticoids inhaled, pneumonia risk

Haemophilus influenzae infections pneumonia

Haemophilus pneumoniae

Hemorrhagic pneumonia

Histopathology of Eosinophilic Pneumonia

Hospital-acquired pneumonia

Hospital-acquired pneumonia management

Hospital-acquired pneumonia prevention

Hydroxypropionic Klebsiella pneumoniae

Hypersensitivity pneumonia

Idiopathic interstitial pneumonia

Idiopathic interstitial pneumonia classification

Idiopathic pneumonia syndrome

In Pneumocystis carinii pneumonia

Infection pneumonia

Infections Klebsiella pneumoniae

Influenza pneumonia following

Intensive care units nosocomial pneumonia

Interferon alfa interstitial pneumonia

Interstitial pneumonia

Interstitial pneumonia fibrosis

Interstitial pneumonia methotrexate

K. pneumoniae

Klebsiella pneumonia

Klebsiella pneumonia infection

Klebsiella pneumonia infection treatment

Klebsiella pneumoniae

Klebsiella pneumoniae (RSKK

Klebsiella pneumoniae IFO

Klebsiella pneumoniae gram-negative

Klebsiella pneumoniae nitrogenases

Klebsiella pneumoniae rates

Klebsiella pneumoniae subsp

Klebsiella pneumoniae subsp aerogenes

Klebsiella pneumoniae, 1,3-propanediol

Late-onset nosocomial pneumonia

Legionella infections pneumonia

Legionella pneumonia

Legionella pneumonia prevention

Legionella pneumophila pneumonia

Levofloxacin in pneumonia

Lipid pneumonia

Lipoid pneumonia

Lobar pneumonia

Lungs pneumonia

Lymphocytic interstitial pneumonia

Lymphoid interstitial pneumonia

Macrolide antibiotics community-acquired pneumonia

Manganese pneumonia

Meningitis Klebsiella pneumoniae

Meningitis Streptococcus pneumoniae

Microbial infectious pneumonia

Minocycline eosinophilic pneumonia

Mortality Associated with Nosocomial Pneumonia

Mycoplasm pneumoniae

Mycoplasma pneumonia

Mycoplasma pneumonia, treatment

Mycoplasma pneumoniae

Mycoplasma pneumoniae infection treatment

Mycoplasma pneumoniae infections

Mycoplasma pneumoniae infections antibiotics

Mycoplasma pneumoniae infections pneumonia

Mycoplasma pneumoniae pneumonia

Nitrogen fixation Klebsiella pneumoniae

Non-specific interstitial pneumonia

Nonspecific interstitial pneumonia

Nonspecific interstitial pneumonia NSIP)

Nonspecific interstitial pneumonia histopathology

Nonventilator-associated nosocomial pneumonia

Nosocomial infections pneumonia

Nosocomial pneumonia antimicrobial therapy

Nosocomial pneumonia bronchoscopy

Nosocomial pneumonia causes

Nosocomial pneumonia clinical evaluation

Nosocomial pneumonia defined

Nosocomial pneumonia diagnosis

Nosocomial pneumonia incidence

Nosocomial pneumonia intervention

Nosocomial pneumonia mortality

Nosocomial pneumonia pathogenesis

Onset Nosocomial Pneumonia

Organizing pneumonia

Organizing pneumonia diagnosis

Organizing pneumonia differential

Organizing pneumonia mechanisms

Organizing pneumonia treatment

Oxygen therapy pneumonia

Patients nosocomial pneumonia

Patients pneumonia

Pediatric patient pneumonia

Penicillin pneumonia

Penicillin-resistant Streptococcus pneumoniae PRSP)

Penicillinase pneumoniae

Penicillins Streptococcus pneumoniae

Pentamidine pneumonia

Pneumococcal infections pneumonia

Pneumococcal pneumonia, treatment

Pneumococcus pneumoniae

Pneumocystis carinii pneumonia

Pneumocystis carinii pneumonia (PCP

Pneumocystis carinii pneumonia treatment

Pneumocystis jiroveci pneumonia

Pneumocystis jirovecii pneumonia

Pneumocystis pneumonia

Pneumonia Chlamydia pneumoniae

Pneumonia INDEX

Pneumonia Subject

Pneumonia anaerobes

Pneumonia antibiotics

Pneumonia antibody

Pneumonia antimicrobials

Pneumonia aspiration

Pneumonia azithromycin effect

Pneumonia bacterial

Pneumonia bronchodilators

Pneumonia case study

Pneumonia chlamydial

Pneumonia clarithromycin effect

Pneumonia clinical presentation

Pneumonia combination therapy

Pneumonia community-acquired

Pneumonia complications

Pneumonia convalescence

Pneumonia death rate

Pneumonia diagnosis

Pneumonia drug-resistant

Pneumonia epidemiology

Pneumonia etiology

Pneumonia evaluation

Pneumonia fluoroquinolones

Pneumonia goals

Pneumonia gram-negative bacteria

Pneumonia gram-positive bacteria

Pneumonia health care-associated

Pneumonia in HIV infection

Pneumonia in children

Pneumonia incidence

Pneumonia laboratory investigations

Pneumonia linezolid

Pneumonia macrolide-azalide

Pneumonia management

Pneumonia mycoplasmal

Pneumonia nosocomial

Pneumonia outcome evaluation

Pneumonia pathogenesis

Pneumonia pathogens

Pneumonia pneumococcal

Pneumonia pneumoniae infections

Pneumonia polysaccharide vaccines

Pneumonia prevention

Pneumonia respiratory acidosis with

Pneumonia ribavirin

Pneumonia risk factors

Pneumonia sepsis and

Pneumonia serum protein

Pneumonia severity assessment

Pneumonia sirolimus

Pneumonia staphylococcal

Pneumonia treatment

Pneumonia tularemia

Pneumonia underlying organism

Pneumonia vaccinations

Pneumonia ventilator-associated

Pneumonia verification

Pneumonia viral

Pneumonia virus of mice

Pneumonia viruses

Pneumonia with AIDS

Pneumonia with kidney disease

Pneumonia zinc supplementation

Pneumonia, atovaquone treatment

Pneumonia, following major

Pneumonia, remedies

Pneumoniae

Polysaccharides Streptococcus pneumoniae type

Postoperative pneumonia

Postoperative pneumonia risk factors

Pseudomonas aeruginosa infections pneumonia

Pseudomonas pneumonia

Psittacosis pneumonia

Pulmonary Pneumonia

Pulmonary system pneumonia

Quinolones community-acquired pneumonia

Respiratory diseases pneumonia

Respiratory disorders pneumonia

Respiratory pneumonia, glucocorticoids

Retention pneumonia

S. pneumoniae

Secondary organizing pneumonia

Secondary organizing pneumonia causes

Sialidase Streptococcus pneumoniae

Sputum nosocomial pneumonia

Staphylococcal infections pneumonia

Staphylococcus aureus and Klebsiella pneumoniae

Staphylococcus aureus pneumonia

Streptococcal pneumonia

Streptococci Streptococcus pneumoniae

Streptococci in pneumonia

Streptococci pneumoniae

Streptococcus pneumonia antibodies

Streptococcus pneumoniae

Streptococcus pneumoniae Pneumococcal vaccine

Streptococcus pneumoniae antibiotic sensitivity

Streptococcus pneumoniae antimicrobial resistance

Streptococcus pneumoniae capsular polysaccharides

Streptococcus pneumoniae conformations

Streptococcus pneumoniae diseases caused

Streptococcus pneumoniae drug-resistant

Streptococcus pneumoniae immunization against

Streptococcus pneumoniae infection

Streptococcus pneumoniae infection treatment

Streptococcus pneumoniae infections caused

Streptococcus pneumoniae infections penicillin-resistant

Streptococcus pneumoniae multidrug-resistant

Streptococcus pneumoniae penicillin resistance

Streptococcus pneumoniae penicillin-resistant

Streptococcus pneumoniae pneumococcus)

Streptococcus pneumoniae pneumonia treatment

Streptococcus pneumoniae polysaccharide vaccines

Streptococcus pneumoniae resistant strains

Streptococcus pneumoniae structure

Streptococcus pneumoniae transformation

Streptococcus pneumoniae treatment

Streptococcus pneumoniae upper respiratory tract infection

Streptococcus pneumoniae vaccine

Streptococcus pneumoniae, capsular

Streptococcus pneumonias

Streptomyces pneumoniae

Surgical patients nosocomial pneumonia

Surveillance for Nosocomial Pneumonia

Systemic sclerosis interstitial pneumonia

Tetracycline in pneumonia

Tetracyclines for bacterial pneumonia

The Clinical-Molecular Interface Pneumonia

Therapy of Selected Pathogens in Nosocomial Pneumonia

Tobramycin in pneumonia

Tuberculosis pneumonia

Ursodeoxycholic acid interstitial pneumonia

Using Quality Improvement Techniques for the Prevention of Nosocomial Pneumonia

Usual interstitial pneumonia

Usual interstitial pneumonia pathology

Ventilator-acquired pneumonia

Ventilator-associated pneumonia bronchoscopy

Ventilator-associated pneumonia defined

Ventilator-associated pneumonia diagnosis

Ventilator-associated pneumonia incidence

Ventilator-associated pneumonia management

Ventilator-associated pneumonia mortality

Ventilator-associated pneumonia pathogenesis

Ventilator-associated pneumonia pathogens

Ventilator-associated pneumonia prevention

Ventilator-associated pneumonia rates

Ventilator-associated pneumonia risk factors

Ventilator-associated pneumonia treatment

Viral infections pneumonia

Viral nosocomial pneumonia

© 2024 chempedia.info